A Functional Polymorphism of the Stromelysin Gene (MMP3) May Influence Disease Progression in HCV Infection

Endoscopy ◽  
2004 ◽  
Vol 36 (05) ◽  
Author(s):  
CP O'Brien ◽  
M O'Brien ◽  
M Curry ◽  
C O'Farrelly ◽  
J Hegarty ◽  
...  
Keyword(s):  
Disease Progression ◽  
Hcv Infection ◽  
Functional Polymorphism

Sorafenib for the treatment of patients with advanced hepatocellular carcinoma and alcoholic cirrhosis.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 352-352
Author(s):  
P. Giovanis ◽  
V. Vincenzi ◽  
C. Manuppelli ◽  
R. Berletti ◽  
M. Marcante ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Disease Progression ◽  
Median Time ◽  
Alcoholic Cirrhosis ◽  
Function Class ◽  
Median Number ◽  
Hcv Infection ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment

352 Background: Hepatocellular carcinoma (HCC) from alcoholic cirrhosis, associated or not with chronic hepatitis C virus (HCV) infection, is a particularly severe liver disease. Scanty and inconsistent data concerning the efficacy of sorafenib in patients (pts) with this disease are available. Methods: Since February 2009 we screened 26 Child-Pugh liver function class A pts bearing the above characteristics. Sixteen of them (61.5%), 15 males and 1 female with median age of 69 years (range 54-79), received 400 mg sorafenib b.i.d. Predominant cause of HCC was alcohol consumption in 13 pts (81.2%), associated with chronic HCV infection in 2 pts (12.5%), and hemosiderosis in 1 pt (6.2%). All pts suffered from multiple comorbidities, and 3 had been previously treated for Burkitt lymphoma, bladder and breast cancer. One pt with prostate cancer was on treatment with androgen blockade. Median number of concomitant medications was 4 (range 2-9). Four pts never received locoregional treatment, and none had received previous antineoplastic therapy. Results: Twelve pts (73%) discontinued sorafenib after a median time of 2 months (range 2-6). The reasons for treatment discontinuation were disease progression (4 pts), liver function deterioration (5 pts), and mild gastrointestinal adverse events (2 pts): 1 pt refused sorafenib treatment after 15 days. 2/4 patients still on treatment with sorafenib at 7, 8, 11, and 18 months showed partial response (RECIST criteria). Seven pts (40%) died because of disease progression at a median time of 5.5 months (range 2-9) and at a median overall survival time of 36 months from diagnosis (range 2-84). Conclusions: Treatment with sorafenib in pts affected by HCC and alcoholic cirrhosis seems effective and well tolerated with high-level compliance. The most common cause of discontinuation was progression of disease and liver function deterioration. No significant financial relationships to disclose.

scholarly journals Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection

Biology ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 55
Author(s):  
Mohammed El-Mowafy ◽  
Abdelaziz Elgaml ◽  
Mohamed El-Mesery ◽  
Salma Sultan ◽  
Tamer A. E. Ahmed ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Gut Microbiota ◽  
Disease Progression ◽  
Disease Status ◽  
Hcv Infection ◽  
Treatment Regimens ◽  
Liver Health ◽  
The Impact ◽  
Gut Microbiota Dysbiosis

The gut–liver-axis is a bidirectional coordination between the gut, including microbial residents, the gut microbiota, from one side and the liver on the other side. Any disturbance in this crosstalk may lead to a disease status that impacts the functionality of both the gut and the liver. A major cause of liver disorders is hepatitis C virus (HCV) infection that has been illustrated to be associated with gut microbiota dysbiosis at different stages of the disease progression. This dysbiosis may start a cycle of inflammation and metabolic disturbance that impacts the gut and liver health and contributes to the disease progression. This review discusses the latest literature addressing this interplay between the gut microbiota and the liver in HCV infection from both directions. Additionally, we highlight the contribution of gut microbiota to the metabolism of antivirals used in HCV treatment regimens and the impact of these medications on the microbiota composition. This review sheds light on the potential of the gut microbiota manipulation as an alternative therapeutic approach to control the liver complications post HCV infection.

Markers of Microbial Translocation Are Elevated in Hepatitis B (HBV) and Hepatitis C (HCV) Infection; A Window Into Biology and Surrogate Markers for Detecting Disease Progression

2011 ◽  
Vol 140 (5) ◽  
pp. S-897
Author(s):  
Christopher Koh ◽  
Netanya G. Sandler ◽  
Annelys Roque ◽  
Jason Eccleston ◽  
David E. Kleiner ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Disease Progression ◽  
Microbial Translocation ◽  
Hcv Infection ◽  
Surrogate Markers

Time of acquisition of HCV infection in renal transplant recipients: a major prognostic factor for disease progression

2012 ◽  
Vol 27 (1) ◽  
pp. 72-79 ◽  
Author(s):  
Ioanna Delladetsima ◽  
Mina Psichogiou ◽  
Vana Sypsa ◽  
Stratigoula Sakellariou ◽  
Angelos Hatzakis ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Renal Transplant ◽  
Disease Progression ◽  
Hcv Infection ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Major Prognostic Factor

Clinical and Biological Implications of Hepatitis C Virus Positivity in Waldenstrom's Macroglobulinemia Patients.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2934-2934
Author(s):  
Alessandra Tedeschi ◽  
Eleonora Vismara ◽  
Marzia Varettoni ◽  
Antonino Greco ◽  
Francesca Ricci ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Disease Progression ◽  
Treatment Time ◽  
Conflicts Of Interest ◽  
Hcv Infection ◽  
Hcv Rna ◽  
Neutrophil Granulocytes ◽  
Increased Risk ◽  
The Impact

Abstract Abstract 2934 Poster Board II-910 Background: hepatitis C virus (HCV) infection has been associated with increased risk of developing B-cell lymphoprolipherative disorders through chronic immune stimulation. Discordant data have been reported about the prevalence of HCV infection in patients with Waldenström's Macroglobulinemia (WM) and the putative role of HCV in lymphomagenesis of this non-Hodgkin Lymphoma subtype remains controversial. Aim: the current retrospective study was conducted to assess the impact of this infection itself in the clinical and biological features and outcome among WM patients as compared with those with HCV negative WM. Patients and methods: we analyzed 140 WM patients with tested anti-HCV antibody (HCV-Ab). HCV-Ab positivity was detected in 21 cases (15%). Clinical characteristics of patients at diagnosis of WM are reported in the table below. Results: HCV positivity was correlated to lower counts of platelets, neutrophil granulocytes, haemoglobin and with presence of cryoglobulins or autoantibodies and splenomegaly. Interestingly we even found a strong link between the presence of HCV and serum parameters of tumor burden such as beta-2 microglobulin (B2-M) and lactate dehydrogenase (LDH). Furthermore we did not reveal any outcome implications in terms of disease progression needing treatment, time from diagnosis to first therapy, overall survival between HCV- and HCV+ patients. Overall, 88 patients (63%) received treatment for disease progression with schedules including Rituximab in 46 cases (52% of treated patients). Rituximab was administered even in HCV-RNA positive patients associated to Cyclophosphamide and Fludarabine and this did not translate in hepatitis development. HCV-RNA was strictly monitored during immunotherapy and we did not observe any significant flair. Conclusions: in our series of patients HCV infection does not seem to affect clinical outcome of disease. Moreover, in our experience patients with documented infection can receive the same schedule of treatment including intensive chemotherapy even with monoclonal antibodies without development of further toxicity. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Xiangjun Qian ◽  
Sujun Zheng ◽  
Leijie Wang ◽  
Mingjie Yao ◽  
Guiwen Guan ◽  
...  
Keyword(s):  
Disease Progression ◽  
Hcv Infection ◽  
Diagnostic Efficiency ◽  
Advanced Fibrosis ◽  
Promising Alternative ◽  
Diagnostic Potential ◽  
Liver Injuries ◽  
Chronic Hcv Infection ◽  
Golgi Protein ◽  
Chronic Hcv

Background and Aim. Serum Golgi protein 73 (GP73) is a promising alternative biomarker of chronic liver diseases, but most data are from patients with HBV infection rather than HCV. Materials and Methods. Two independent cohorts of chronic hepatitis C (CHC) patients from the 5th Medical Centre of the Chinese PLA General Hospital (n=174) and Beijing Youan Hospital (n=120) with different histories of HCV infection were enrolled. The correlations between serum GP73 and other biochemical indices, as well as its correlations with different stages of liver disease progression, were investigated. The receiver operating characteristic (ROC) curve was employed to evaluate the diagnostic potential of serum GP73 for liver necroinflammation and fibrosis, and comparisons of the diagnostic efficiency with traditional indices of hepatic liver injuries were further investigated. Results. Levels of serum GP73 were found significantly elevated in patients with moderate to severe inflammatory grade (G≥2) and/or with advanced fibrotic stages (F≥3) in both cohorts (P<0.05, respectively), as compared to those with a normal or mild liver lesion. Further ROC analysis demonstrated that serum GP73 was comparable to serum ALT and AST in diagnosing the liver necroinflammation grade at G≥2, but its diagnostic values for advanced fibrosis (F≥3) and cirrhosis (F=4) were limited when compared to APRI and FIB-4, and FIB-4 exhibited the best performance. Notably, an obvious elevation of serum GP73 was observed after patients received PEG-IFN and ribavirin treatment. Conclusions. Serum GP73 is an important biomarker in evaluating and monitoring the disease progression including liver necroinflammation and fibrosis in patients with chronic HCV infection, but the value is limited for diagnosing advanced fibrosis and cirrhosis in comparison with APRI and FIB-4.

scholarly journals The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132772 ◽  
Author(s):  
Jamie Inshaw ◽  
Clifford Leen ◽  
Martin Fisher ◽  
Richard Gilson ◽  
David Hawkins ◽  
...  
Keyword(s):  
Disease Progression ◽  
Hcv Infection ◽  
Hiv Disease ◽  
The Uk ◽  
The Impact

scholarly journals HIV/HCV Co-infection, Liver Disease Progression, and Age-Related IGF-1 Decline

2017 ◽  
Vol 2 (1) ◽  
pp. 50 ◽  
Author(s):  
Jeffrey Quinn ◽  
Jacquie Astemborski ◽  
Shruti H. Mehta ◽  
Gregory D. Kirk ◽  
David L. Thomas ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Linear Regression ◽  
Hiv Infection ◽  
Disease Progression ◽  
Hcv Infection ◽  
Age Related ◽  
Liver Disease Progression ◽  
Over Time

Background: We have previously reported that persons co-infected with HIV and hepatitis C virus (HCV) had liver disease stages similar to HIV-uninfected individuals who were approximately 10 years older. Insulin-like growth factor 1(IGF-1) levels have long been known to decline with advancing age in humans and non-humans alike. We examined whether HIV infection affects the expected decline in IGF-1 in persons with chronic hepatitis C virus (HCV) infection and if that alteration in IGF-1 decline contributes to the link between HIV, aging, and liver disease progression.Methods: A total of 553 individuals with HCV infection were studied from the AIDS Linked to the Intravenous Experience (ALIVE) cohort for whom more than 10 years of follow-up was available. Serum IGF-1 levels were determined by ELISA and evaluated according to baseline characteristics and over time by HIV status and liver disease progression. Linear regression with generalized estimating equations was used to determine whether IGF-1 decline over time was independently associated with liver disease progression.Results: Baseline IGF-1 levels were strongly associated with age (P < 0.0001) but not with gender or HIV infection. Levels of IGF-1 declined at a rate of -1.75 ng/mL each year in HCV mono-infected individuals and at a rate of -1.23 ng/mL each year in HIV/HCV co-infected individuals (P < 0.05). In a multivariable linear regression model, progression of liver fibrosis was associated with HIV infection and age, as well as with a slower rate of IGF-1 decline (P = 0.001); however, the rate of IGF-1 decline did not alter the strength of the associations between HIV, liver disease, and age.Conclusions: The normal decline in IGF-1 levels with age was attenuated in HIV/HCV co-infected individuals compared to those with HCV mono-infection, and slower IGF-1 decline was independently associated with liver disease progression. Keywords: IGF-1, HIV-1, Hepatitis C, Fibrosis, Liver

Sign in / Sign up

Export Citation Format

Share Document